The Ustekinumab Injection treatment manufactured by biotech company Qyuns Therapeutics, located in the Taizhou Medical High-tech Zone in Taizhou city, East China's Jiangsu province, was recently approved for marketing.
Used to treat adults with moderate to severe plaque psoriasis, the product was co-developed by Qyuns Therapeutics and pharma company Huadong Medicine, which is based in Hangzhou city, capital of Zhejiang province.
One advantage of the product is that it is currently the least frequently injected biological preparation for treating psoriasis in China. For patients, a maintenance period of one year only requires four injections.
At present, the treatment of psoriasis in China has entered the biologics phase. Compared with traditional treatment methods, biologics have significant advantages in efficacy, safety and treatment time, especially in the treatment of severe, difficult to treat and special types of psoriasis.
To date, Qyuns Therapeutics has established a comprehensive drug supply pipeline, covering major areas of the skin, rheumatism, respiratory and digestive diseases.
As a result, it has become one of leading enterprises in the field of autoimmune and allergic diseases in China.
An exterior view of Qyuns Therapeutics, founded in the Taizhou Medical High-tech Zone in 2015. [Photo/WeChat account: weigg6666]